Accepted answer
The honest answer is that mild elevation is very common, that it usually improves with weight loss, and that the exceptions are the reason anyone checks.
Hy's law describes the combination that matters: transaminases above three times the upper limit together with bilirubin above twice the upper limit and no cholestatic explanation. That combination is a signal; isolated mild transaminase elevation is not.
Headline results, principal programmes
| Trial | Agent | n | Duration | Primary result |
|---|
| STEP 1 | Semaglutide 2.4 mg | 1,961 | 68 wk | −14.9 % vs −2.4 % weight |
| STEP 2 | Semaglutide 2.4 mg, T2DM | 1,210 | 68 wk | −9.6 % vs −3.4 % weight |
| SURMOUNT-1 | Tirzepatide 5/10/15 mg | 2,539 | 72 wk | −15 / −19 / −21 % weight |
| SURMOUNT-4 | Tirzepatide, withdrawal | 670 | 88 wk | Continued loss vs substantial regain |
| SELECT | Semaglutide 2.4 mg | 17,604 | ~40 mo | MACE HR 0.80 (0.72–0.90) |
| FLOW | Semaglutide 1.0 mg, CKD | 3,533 | ~3.4 yr | Renal composite reduced; stopped early |
| SURMOUNT-OSA | Tirzepatide, OSA | 469 | 52 wk | AHI reduced with and without PAP |
Concretely, very rapid weight loss can transiently worsen liver biochemistry, which is one of several arguments against pursuing the steepest possible trajectory.
Trials in this class have generally reported improvement rather than deterioration in liver biochemistry, consistent with the weight-mediated mechanism.
Research-use material of unknown content is an unquantifiable variable in any such attribution.
Isolated mild elevation is common and usually improves with weight loss.